Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma
Phase 4
25 Years
75 Years
25 Years
75 Years
Open (Enrolling)
Both
Hepatitis C, Chronic
Both
Hepatitis C, Chronic
Trial Information
Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma
Inclusion Criteria:
- Clinical diagnosis of Hepatocellular carcinoma due to Chronic Hepatitis C Virus
Infection.
- Must be treated with curative treatment for primary tumor using either surgical
resection or radiofrequency ablation therapy
Exclusion Criteria:
- No recurrence of hepatocellular carcinoma 3 months after the primary treatment
- Renal dysfunction
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Outcome Measure:
Incidence of adverse effect of interferon
Outcome Time Frame:
During the treatment period
Safety Issue:
Yes
Principal Investigator
Tsutomu Chiba, M.D.,Ph.D.
Investigator Role:
Study Chair
Investigator Affiliation:
Kyoto University
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
O2006-415
NCT ID:
NCT00375661
Start Date:
September 2006
Completion Date:
February 2013
Related Keywords:
- Hepatitis C, Chronic
- hepatocellular carcinoma
- Carcinoma
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Carcinoma, Hepatocellular
Name | Location |
|---|
